Clinical Trials
89 trialsNCT06172296 2026-05-27
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
National Cancer Institute (NCI)
Phase 3 Recruiting
NCT00734877 2026-05-22
TT4B
University of Arkansas
Phase 3 Active not recruiting
NCT06022939 2026-05-06
Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis
SWOG Cancer Research Network
Phase 3 Recruiting
NCT00114101 2026-04-29
Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT00602641 2026-04-29
Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT07396480 2026-03-17
Fludarabine Plus Melphalan Versus Addition of Venetoclax to Fludarabine/Melphalan Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in AML/MDS Patients Aged > 50 Years: a Multicenter, Randomized, Phase 3 Trial
First Affiliated Hospital of Zhejiang University
Phase 3 Recruiting
NCT03126916 2026-02-27
Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
Children's Oncology Group
Phase 3 Recruiting
NCT01208766 2026-01-06
HO95
Stichting Hemato-Oncologie voor Volwassenen Nederland
Phase 3 Completed
NCT05457556 2025-12-22
Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome
Children's Oncology Group
Phase 3 Active not recruiting
NCT02195479 2025-08-22
A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma
Janssen Research & Development, LLC
Phase 3 Completed
NCT05991908 2025-02-18
Randomized Study of Conditioning of Fludarabine Combined With Single or Dual Alkylating Agents in Myeloid Malignancies
Shanghai Jiao Tong University School of Medicine
Phase 3 Recruiting
NCT06829472 2025-02-17
Conditioning Regimen of Melphalan-busulfan and Fludarabine: a Randomized Study of Different Dose of Melphalan
Shanghai Jiao Tong University School of Medicine
Phase 3 Recruiting
NCT05674539 2025-02-10
Reduced Intensity Conditioning Regimens for Acute Myeloid Leukemia and Myelodysplastic Syndrome
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 3 Enrolling by invitation
NCT05477589 2024-12-19
SCRIPT-AML
Vastra Gotaland Region
Phase 3 Recruiting
NCT01093196 2024-11-07
Lenalidomide and Dexamethasone Versus Melphalan Prednisone and Lenalidomide Versus Cyclophosphamide, Prednisone and Lenalidomide in Elderly Multiple Myeloma Patients
Fondazione EMN Italy Onlus
Phase 3 Completed
NCT01091831 2024-11-06
Cyclophosphamide, Lenalidomide and Dexamethasone (CRD) Versus Melphalan (200 mg/m2) Followed By Autologous Stem Cell Transplant (ASCT) In Newly Diagnosed Multiple Myeloma Subjects
Fondazione EMN Italy Onlus
Phase 3 Completed
NCT06613035 2024-09-25
Twice-per-weekSelinexor, 2 Days Melphalan
Institute of Hematology & Blood Diseases Hospital, China
Phase 3 Not yet recruiting
NCT00551928 2024-07-22
MPRvsMEL200
Fondazione EMN Italy Onlus
Phase 3 Completed
NCT03217812 2024-04-25
A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region)
Janssen Research & Development, LLC
Phase 3 Completed
NCT02678572 2023-12-21
FOCUS
Delcath Systems Inc.
Phase 3 Completed
NCT05022901 2023-12-21
An Open-Label Expanded Access Study of the Melphalan/Hepatic Delivery System (HDS) in Patients With Hepatic Dominant Ocular Melanoma
Delcath Systems Inc.
Phase 3 Active not recruiting
NCT01063179 2023-06-29
Velcade, Melphalan, Prednisone And Thalidomide Versus Velcade, Melphalan, Prednisone in Multiple Myeloma Patients
Fondazione EMN Italy Onlus
Phase 3 Completed
NCT01339910 2023-01-04
BMT CTN 0901
Medical College of Wisconsin
Phase 3 Terminated
NCT02063022 2022-09-19
EW-1
Italian Sarcoma Group
Phase 3 Completed
NCT05466318 2022-07-25
ChiCGB vs BEAM in High-risk or R/R Lymphomas
Sichuan University
Phase 3 Unknown
NCT02197221 2022-05-23
IFM2014-02
University Hospital, Toulouse
Phase 3 Completed
NCT00567567 2022-04-28
Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma
Children's Oncology Group
Phase 3 Completed
NCT01078454 2022-02-01
Melphalan and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Systemic Light-Chain Amyloidosis
National Cancer Institute (NCI)
Phase 3 Completed
NCT00324727 2021-06-21
Hepatic Arterial Infusion With Melphalan Compared With Standard Therapy in Treating Patients With Unresectable Liver Metastases Due to Melanoma
Delcath Systems Inc.
Phase 3 Completed
NCT04799002 2021-03-16
Topotecan and Melphalan for Retinoblastoma
Sun Yat-sen University
Phase 3 Recruiting
NCT01704716 2020-10-23
High Risk Neuroblastoma Study 1.8 of SIOP-Europe (SIOPEN)
St. Anna Kinderkrebsforschung
Phase 3 Recruiting
NCT01413178 2020-04-21
A Randomized Trial to Compare Busulfan + Melphalan 140 mg/m2 With Melphalan 200 mg/m2 as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma
M.D. Anderson Cancer Center
Phase 3 Completed
NCT00002678 2020-04-02
Combination Chemotherapy in Treating Patients With Multiple Myeloma
Canadian Cancer Trials Group
Phase 3 Completed
NCT00689936 2019-11-20
FIRST
Celgene
Phase 3 Completed
NCT00137995 2019-08-28
R-ICE Versus R-DHAP in Patients Aged 18-65 With Relapse Diffuse Large B-cell Lymphoma
Lymphoma Study Association
Phase 3 Completed
NCT01818752 2019-08-26
CLARION
Amgen
Phase 3 Completed
NCT00002835 2018-11-15
Combination Chemotherapy in Treating Patients With Lymphoma
M.D. Anderson Cancer Center
Phase 3 Completed
NCT02489500 2018-09-10
VelRand
Boston Medical Center
Phase 3 Terminated
NCT02366663 2018-03-12
SPINOZA
City of Hope Medical Center
Phase 3 Terminated
NCT00083915 2017-11-20
DTPACE Followed by Tandem Transplant With Melphalan (MEL) 200 Versus MEL/Dexamethasone/Thalidomide (DT) Platinol/Adriamycin/Etoposide (PACE) Hybrid and DTPACE Consolidation
University of Arkansas
Phase 3 Completed
NCT01916252 2017-09-27
GEM2012MENOS65
PETHEMA Foundation
Phase 3 Completed
NCT01277016 2017-03-10
EMN-03
European Myeloma Network B.V.
Phase 3 Completed
NCT00920153 2016-09-16
Three Different Therapy Regimens in Treating Patients With Previously Untreated Hodgkin Lymphoma
French Innovative Leukemia Organisation
Phase 3 Terminated
NCT00477971 2016-05-17
Low-Dose Melphalan and Dexamethasone Compared With High-Dose Melphalan Followed By Autologous Stem Cell Transplant in Treating Patients With Primary Systemic Amyloidosis
Mayo Clinic
Phase 3 Completed
NCT00892346 2016-05-10
Single Autologous Stem Cell Transplantation Followed by Maintenance Therapy as Front-line Treatment for Myeloma
Shanghai Jiao Tong University School of Medicine
Phase 3 Suspended
NCT00083551 2015-11-23
UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy
University of Arkansas
Phase 3 Completed
NCT00217438 2015-08-21
Melphalan and Amifostine Followed By One or Two Autologous or Syngeneic Stem Cell Transplants and Maintenance Therapy in Treating Patients With Stage II-III Multiple Myeloma
Fred Hutchinson Cancer Center
Phase 3 Completed
NCT00002548 2015-03-06
SWOG-9321 Melphalan, TBI, and Transplant vs Combo Chemo in Untreated Myeloma
SWOG Cancer Research Network
Phase 3 Completed
NCT02288741 2014-11-11
DSMM-II
WiSP Wissenschaftlicher Service Pharma GmbH
Phase 3 Completed
NCT00020566 2014-06-24
Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation, Radiation Therapy, and/or Surgery in Treating Patients With Ewing's Sarcoma
National Cancer Institute (NCI)
Phase 3 Unknown